2016 is on track for its second CRISPR/Cas9 IPO

Robert Weisman, Boston Globe, 11 April 2016 https://www.bostonglobe.com/business/2016/04/11/intellia-plans-ipo-strikes-deal-with-regeneron/LigZmVRwOWoDZv3klrGlfM/story.html

Cambridge startup Intellia Therapeutics Inc. filed Monday 11 April for an IPO seeking to raise $120 million.  Intellia Therapeutics also announced a collaboration with Regeneron Pharmaceuticals Inc., with Intellia receiving $75 million up front with the possibility for royalty payments if Regeneron successfully markets 10 gene-editing drugs developed from Intellia’s technology.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply